Search Orphan Drug Designations and Approvals
-
Generic Name: | An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4 |
---|---|
Date Designated: | 02/13/2023 |
Orphan Designation: | Treatment of facioscapulohumeral muscular dystrophy (FSHD) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, California 92121 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-